Krystal Biotech, Inc. (KRYS)

Market Cap	7.72B +68.1%
Revenue (ttm)	389.13M +33.9%
Net Income	204.83M +129.7%
EPS	6.84 +128.0%
Shares Out	29.23M
PE Ratio	38.61
Forward PE	33.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,491
Open	280.00
Previous Close	283.29
Day's Range	259.58 - 281.69
52-Week Range	122.80 - 298.30
Beta	0.48
Analysts	Strong Buy
Price Target	281.45 (+6.56%)
Earnings Date	Feb 17, 2026

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 295
• Stock Exchange: NASDAQ
• Ticker Symbol: KRYS
• Website: https://www.krystalbio.com

Financial Performance

In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.

Analyst Summary

According to 11 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $281.45, which is an increase of 6.56% from the latest price.

Price Target

$281.45

(6.56% upside)

Analyst Consensus: Strong Buy